Drugs / PCX12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06217666 | Dec 2026 → Dec 2028 expected | pancreatic adenocarcinoma | Haoming (Carl) Qiu | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PCX12 | “Subjects with undergo standard of care radiation therapy and then start on PCX12 therapy starting at 200 ng/kg of PCX12 escalating to a potential maximum dosage of 800 ng/kg of...” NCT06217666 ↗ |
| Route | Other | “Delivered by Intratumoral Injection” NCT06217666 ↗ |